AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca and GSK fall after Trump renews pharma tariff threat
Shares in AstraZeneca PLC (LSE:AZN), the largest company on the FTSE 100 index, and fellow blue chip GSK PLC (LSE:GSK, NYSE:GSK) were down 1.4% and 1.9% respectively on renewed worries about US drug tariffs. The pharmaceutical pair were a large drag on the London index after US President Donald Trump said tariffs on imported drugs could be imposed “very soon”, echoing comments from two months ago.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) concluded the recent trading session at $73.55, signifying a -1.17% move from its prior day's close.
AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration
AstraZeneca PLC (LSE:AZN) is betting big on AI-enabled drug discovery (and China), agreeing a research collaboration with China's CSPC Pharmaceutical Group that could see the Anglo-Swedish drugmaker pay up to $3.6 billion in milestone payments. The deal focuses on developing new oral treatments for chronic conditions, with both companies contributing to the discovery and development of pre-clinical candidates.
AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion
The deal with China's CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of new drug candidates.
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC
AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.
Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes
UBS has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, offering potential upside of just over 30% from the current share price of 10,907p. The focus is on two high-profile drug candidates with contrasting outlooks.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.
AstraZeneca CEO Pascal Soriot on breast cancer drug trial
Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
